Carisma's CEO discusses their Moderna-partnered CAR-M preclinical late breaker at #SITC23
Steven Kelly describes how Carisma is leveraging Moderna's mRNA and LNP expertise to engineer monocytes in-vivo to act as a cell therapy against cancer.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
.png){kind=logo}
The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants
bottom of page
Commenti